Positive Results From Affinium Pharmaceuticals' Phase 2a Clinical Trial of AFN-1252 in ABSSSI
3/21/2013 7:36:16 AM
More...
|
Affinium Pharmaceuticals Announces Completion of Recruitment for Phase 2 Clinical Trial of AFN-1252 in Acute Bacterial Skin & Skin Structure Infections
8/7/2012 10:36:13 AM
More...
|
Affinium Pharmaceuticals Announces Results of AFN-1252 Multiple Ascending Dose Phase I Clinical Trial
5/2/2011 8:45:39 AM
More...
|
Affinium Pharmaceuticals to Present at Super Bugs - Super Drugs Conference in London, UK
3/15/2011 6:44:34 AM
More...
|
Affinium Pharmaceuticals Announces the Initiation of a Phase I Clinical Trial Using an Optimized Oral Formulation of AFN-1252, its Novel Anti-staphylococcal Antibiotic
4/12/2010 10:55:19 AM
More...
|
GlaxoSmithKline (GSK), Novartis AG, Pfizer Inc. (PFE), AstraZeneca AB, Albert Einstein College of Medicine, Centers for Disease Control and Prevention (CDC), And AstraZeneca AB Explore Advances in Anti-Infective Drug Development
12/9/2009 10:35:53 AM
More...
|
Affinium Pharmaceuticals Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
3/4/2008 8:49:13 AM
More...
|
Affinium Pharmaceuticals Welcomes Dr. Barry Hafkin as Chief Medical Officer
4/2/2007 12:50:15 PM
More...
|
Affinium Pharmaceuticals Closes US$18 Million Series A to Advance Clinical Development of Novel Antibacterial Compound
3/26/2007 12:57:57 PM
More...
|
Accium BioSciences, Inc. To Provide Microdosing Services To Affinium Pharmaceuticals In Support Of A Biodefense Research Contract
2/12/2007 12:24:21 PM
More...
|
|